Finny logo
Finny logo
Dibs:
Dibs:
0

Progenics Pharmaceuticals (PGNX) earnings: expect 16% revenue growth

12:50 pm ET, 07 May 2019

Progenics Pharmaceuticals Inc. (PGNX) is announcing earnings on May 08. Wondering what revenue and earnings will look like?

What should you expect from the upcoming earnings?

Revenue for the next quarter is expected to be $4M, which implies 16% growth rate year-over-year.

Earnings per share are expected to come in at $-0.24. If this materializes, EPS will decline -26% year-over-year.

How did the stock do last month?

Over the last month, Progenics Pharmaceuticals Inc. (PGNX) returned +13.83%.

What do analysts say about the stock?

Progenics Pharmaceuticals Inc. (PGNX) average analyst price target is 96.11% above its current price ($5.14).

For the latest price and information on Progenics Pharmaceuticals Inc., please visit Finstead and ask for "PGNX", "PGNX analysis" or "PGNX news".

Progenics Pharmaceuticals Inc. (PGNX) Stock Guide

Updated at: 10:29 am ET, 18 Sep 2020

Before we start: if you're looking for PGNX stock price, you can quickly find it out by visiting Finny and typing "PGNX quote". If you're looking for a quick scoop on PGNX stock (chart, price target, market cap, news and buy or sell analysis), go to Finny and look for "PGNX". You'll get all this info in one place. Or you can just type "PGNX news" to get the latest stock news.

Looking to buy or sell Progenics Pharmaceuticals Inc. (PGNX)? Interested in getting the full scoop on PGNX, including earnings and dividends, stock forecast, buy or sell analysis and key stats? If so, you came to the right place.

In this PGNX stock guide, we'll address key questions about PGNX, above and beyond what you can find on Yahoo Finance, Zacks, MarketWatch or Morningstar.

Here is what you'll be able to find in this guide:

Analyst Predictions: stock forecast and analyst ratings;
Analysis: Finny Score and buy or sell analysis;
Key Stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio, industry, sector, and number of employees.

And here is the list of questions we'll answer:
1. What is PGNX stock forecast (i.e., prediction)?
2. PGNX buy or sell? What is PGNX Finny Score?
3. What are the reasons to buy PGNX? Why should I buy PGNX stock?
4. What are the reasons to sell PGNX? Why should I sell PGNX stock?
5. What are PGNX key stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

So let's start. Scroll down to the question that interests you the most.

Analyst Predictions

1. What is PGNX stock forecast (i.e., prediction)?

Based on PGNX analyst price targets, PGNX stock forecast is $6.75 (for a year from now). That means the average analyst price target for PGNX stock is $6.75. The prediction is based on 4 analyst estimates.

The low price target for PGNX is $6.50, while the high price target is $7.00.

PGNX analyst rating is Strong Buy.

Analysis

2. PGNX buy or sell? What is PGNX Finny Score?

#{finnyScore:null}Our quantitative analysis shows 3 reasons to buy and 0 reasons to sell PGNX. PGNX doesn’t have an assigned Finny Score, because we don’t have sufficient data points to score the stock.

3. What are the reasons to buy PGNX? Why should I buy PGNX stock?

Here are the reasons to buy PGNX stock:

4. What are the reasons to sell PGNX? Why should I sell PGNX stock?

We can’t think of any good reason to sell this stock, which doesn’t mean they don’t exist.

Key Stats

5. What are PGNX key stats : revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

Let's look at the key statistics for PGNX:

Metrics PGNX
Price $4.27
Average Price Target / Upside $6.75 / 58.08%
Average Analyst Rating Strong Buy
Forward Dividend Yield 0.00%
Industry Biotechnology
Sector Healthcare
Number of Employees 64
Market Cap $355.05M
Forward P/E Ratio -6.31
Price/Book Ratio N/A
Revenue (TTM) N/A
YoY Quarterly Revenue Growth N/A
Profit Margin N/A

If you liked this analysis, check out Stock Guides for other stocks.

Follow Us